Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

BACKGROUND: ErbB2/HER2 oncoprotein often drives breast cancers (BCs) which are treated with the anti-ErbB2 antibody trastuzumab. The efficacy of trastuzumab-based metastatic BC therapies is routinely assessed by imaging studies. Trastuzumab typically becomes ineffective in the case of this disease a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Durcker, Arik, Yoo, Byong Hoon, Khan, Iman Aftab, Choi, Dongsic, Montermini, Laura, Liu, Xiaoyang, Jovanovic, Sanja, Younis, Tallal, Rosen, Kirill V.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7541295/
https://ncbi.nlm.nih.gov/pubmed/33023655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01342-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars